ENHERTU (fam-trastuzumab deruxtecan-nxki) gets US FDA nod for HER2-positive advanced gastric cancer EP News Bureau Jan 18, 2021 The results from the DESTINY-Gastric01 trial showed a 41 per cent improvement in survival and a response rate more than three…
